Venclexta Adverse Event Report 2018

$19.99

This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions

Description

Venclexta (venetoclax) inhibits a certain protein in cancer cells (abnormal lymphocytes produced in chronic lymphocytic leukemia) that helps keep those cells alive and makes them resistant to chemotherapy. Venetoclax binds to this protein, which helps kill the cancerous lymphocytes in blood and bone marrow. Venclexta is used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) in adults with or without 17p deletion (a specific genetic marker). Venclexta is sometimes used in combination with rituximab to treat these conditions. Venclexta is also used in combination with azacitidine, decitabine, or cytarabine to treat acute myeloid leukemia. This combination is for use in adults who are 75 years or older, or who cannot use standard chemotherapy due to other medical conditions. Venclexta is sometimes given after other treatments have failed.https://www.drugs.com/venclexta.html